A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Philip M. Arlen(Dana-Farber Cancer Institute), William L. Dahut(National Cancer Institute), Jennifer L. Marté(National Cancer Institute), Patricia K. Beetham(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Jarett L. Feldman(National Cancer Institute), Douglas W. Grosenbach(National Institutes of Health), Jeffrey Schlom(National Cancer Institute), Dennis Panicali(Fox Chase Cancer Center), James L. Gulley(National Cancer Institute), Mary Pazdur(National Institutes of Health), Clara Chen(National Institutes of Health Clinical Center), Kwong Y. Tsang(Center for Biologics Evaluation and Research), Elizabeth C. Jones(National Institutes of Health Clinical Center), Catherine Parker(National Cancer Institute), Lisa Skarupa(National Institutes of Health)
Cited by 291
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Importance of the nef gene for maintenance of high virus loads and for development of AIDS
|Cell|1991|1.6k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817